Personalis Reports Third Quarter Results
Business Wire•04/11/2026•16:01 ET
0
Key Highlights
- ➤Total revenue $25.6 million versus $14.5 million year over year
- ➤Clinical revenue $4.4 million versus $0.4 million; test volume reached 13,157
- ➤Net loss widened to $33.8 million from $21.7 million year over year
- ➤Cash, cash equivalents, and short-term investments totaled approximately $190.6 million
- ➤Personalis and Tempus merger means Personalis will no longer provide financial guidance
Expert Statements
Chris Hall, Chief Executive Officer of Personalis
“These results reflect the strength of our team’s execution and commitment to helping transform the active management of cancer through more informed care”
Chris Hall, Chief Executive Officer of Personalis
“Combining with Tempus gives us the scale, complementary capabilities and resources to accelerate innovation and deliver even greater value to patients, clinicians, and biopharma partners.”
Reports Q3 clinical test volume of 13,157, clinical revenue of $4.4 million and overall revenue of $25.6 million
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the third quarter ended September 30, 2026.
Get started
Create a free account to read the full story.